Gapping up
In reaction to strong earnings/guidance:
- N/A.
Other news:
- TSLA +16.7% (settles SEC investigation; Elon Musk will step down as Tesla's Chairman, will be ineligible to be re-elected Chairman for 3 years; Musk and Tesla will each pay a separate $20 million penalty)
- IGC +14.7% (enters into $15 mln common stock At-the-Market Offering Agreement with The Benchmark Company and ViewTrade Securities)
- GE +14.3% (names H. Lawrence Culp, Jr. as CEO and Chairman)
- TLRY +8.6% (receives sales license from Health Canada to sell cannabis under the Access to Cannabis for Medical Purposes Regulations)
- CORT +8.1% (FDA has granted orphan drug status to Corcept's selective cortisol modulator relacorilant to treat patients with pancreatic cancer)
- ADMA +7.7% (resubmits Biologics License Application for RI-002)
- TRXC +5.5% (receives CE Mark approval for its Senhance Ultrasonic Instrument System)
- AVEO +4.2% (initiates topline analysis of the phase 3 TIVO-3 clinical trial)
- INSY +3.9% (signs definitive license agreement with Lunatus to commercialize Subsys)
- PX +2.7% (Linde (LNAGF) receives approval from China for PX merger)
- HSIC +1.1% (Henry Schein, Patterson Companies (PDCO) and Benco Dental Supply agree to settlement related to Supplies Antitrust Litigation)
Analyst comments:
- LOGM +3.8% (upgraded to Outperform from Perform at Oppenheimer)
- TEVA +3.7% (added to Conviction Buy List at Goldman)
- ENTG +2.6% (upgraded to Buy from Hold at Deutsche Bank)
- BCS +2.1% (upgraded to Buy from Hold at Berenberg)
- UPS +1.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- MTB +1.5% (upgraded to Outperform from In-line at Evercore ISI)
- STOR +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
![]()